PSAT1 and myocardial infarction: The clinical potential of PSAT1 modRNA for ischemic heart diseases is promising, offering benefits such as promoting cardiomyocyte proliferation, inhibiting oxidative stress and cell death, enhancing cardiac repair, and improving post-MI function.